While survival rates for most cancers continue to improve in Australia, brain cancers aren’t seeing the same success. Australians diagnosed with brain cancer had around a 25% chance of surviving for five years from 2009 to 2013. This was compared to a survival rate of 68% for all cancers combined in the same period.
Brain and central nervous system cancers (CNS) can be either malignant or benign, but unlike benign tumours in other tissues, all brain and CNS tumours are associated with significant sickness and death.
It is estimated that 2,076 new cases of brain and other CNS cancers will be diagnosed in Australia in 2017. Around 1,500 people will die from this disease.
While the survival rate is 25% for brain cancer in general, for certain brain cancers it’s much worse. For instance, glioblastoma, the most common form of brain cancer in adults, has a five year survival rate of 4.6%.
So why hasn’t there been an improvement in survival in the last 30 years for patients with brain tumours? A frequent problem is that it’s hard for drugs to actually get to the tumour. The brain has a unique defence, termed the “blood-brain barrier”, that limits the passage of drugs from the bloodstream into the brain.
Indeed, most chemotherapies are stopped from getting to the brain by the blood-brain barrier. Those that do, such as temozolomide used to treat brain tumours including glioblastoma, unfortunately have limited efficacy, and only improve survival by several months at best. There is clearly a desperate need to identify new drug targets and more effective therapies for brain tumour treatment.
Incidence rates for brain and CNS cancers have stayed steady for some decades but the sickness and death that comes with the disease continues to affect many Australian lives. A recent report from the Australian Institute of Health and Welfare shows that the incidence of many cancers has increased over time.
The incidence of some other cancers has decreased though. In the case of lung cancer, this is likely due to a decrease in smoking. While the introduction of a vaccine for the human papillomavirus (HPV) (which is responsible for most cases of cervical cancer) would explain the drop in cervical cancer rates.
In comparison, the overall incidence of brain cancer has remained stable over the last 30 years, probably because there are no known lifestyle or environmental factors that contribute to these cancers. While we don’t know what causes brain and CNS tumours, there is evidence to suggest genetics and high levels of radiation may play a role.
While many cancers almost exclusively present in older people, this is not the case with brain tumours, as these kill more people under 40 than any other cancer.
Perhaps of most concern is that brain tumours disproportionately affect children, killing more children (aged 1-14 years old) in Australia than any other disease. They are only third to land transport accidents and congenital and associated abnormalities as causes of child death in Australia.
The prognosis for children with brain cancers, the most common being medulloblastoma, is much better than in adults though. Around 70% of these patients will have curable disease.
But, undergoing life-saving treatment such as surgery, chemotherapy and radiation comes at a long-term cost for these children, as these therapies themselves are associated with detrimental effects on childhood development. These can potentially result in neurological defects, learning difficulties, growth abnormalities and mental health issues.
The Australian government recently announced a A$100 million dollar medical research fund committed to doubling the survival rates and improving the quality of life of patients with brain cancer over the next ten years. It is hoped with this substantial investment, progress will be made to eventually defeat brain cancer.
Melinda Tea, Research Associate, Centre for Cancer Biology, University of South Australia and Stuart Pitson, NHMRC Senior Research Fellow, Centre for Cancer Biology, University of South Australia
This article was originally published on The Conversation. Read the original article.